Following US pharmaceutical giant Pfizer’s failed attempt to acquire AstraZeneca, reports say Pfizer has inked a new joint venture deal to develop immunotherapy cancer drugs.
According to reports, Pfizer will team up with France-based Cellectis. The partnership involves Pfizer paying Cellectis $80 million upfront, as well as funding for ongoing research into the new treatment.
Among the other aspects of the deal, Pfizer will also acquire a 10 percent stake in the French company.
The joint venture was announced Wednesday and follows last month’s failure for Pfizer to convince AstraZeneca to merge. Pfizer raised its bid as high as $118 billion to purchase the UK firm.
Full content: Yahoo News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI